Print this page
-
Phase 2 Study of INCMGA00012 and the Oncolytic Virus Pelareorep in Metastatic Triple Negative Breast Cancer.
Protocol: 042001Principal Investigator:
- Mridula George (Rutgers University)
Applicable Disease Sites: Breast -
Cancer treatment and survivorship experiences among Southern New Jersey residents.
Protocol: 131803Principal Investigator:
- Sharon Manne PhD (Rutgers University)
Applicable Disease Sites: Colon
Breast - Female
Melanoma, Skin
Ovary
Lung
Rectum
Cervix
Other Female Genital
Thyroid
Prostate
Urinary Bladder -
Awareness, attitudes, and apprehensions about breast cancer among South Asians living in the U.S
Protocol: 132013Principal Investigator:
- Jaya Satagopan (School of Public Health)
Applicable Disease Sites: Breast -
R3767-ONC-1613: A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (anti-LAG-3 mAb) Administered Alone or in Combination with REGN2810 (anti-PD-1 mAb) in Patients with Advanced Malignancies
Protocol: 051706Principal Investigator:
- Jyoti Malhotra MD, MPH (Rutgers University)
Applicable Disease Sites: Melanoma, Skin
Kidney
Non-Hodgkin's Lymphoma
Lung
Breast - Female -
NCI/CTEP #10291: A Phase 1b Study of M6620 in Combination with Radiation Therapy to Overcome Therapeutic Resistance in Chemotherapy Resistant Triple Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer.
Protocol: 051913Principal Investigator:
- Nancy Chan M.D (Rutgers University)
Applicable Disease Sites: Breast -
BTCRC-BRE16-042: A Phase II Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients: Big Ten Cancer Research Consortium
Protocol: 041705Principal Investigator:
- Nancy Chan M.D (Rutgers University)
Applicable Disease Sites: Breast - Female
Breast - Male
